南京医药
(600713)
| 流通市值：68.10亿 | | | 总市值：69.11亿 |
| 流通股本：12.90亿 | | | 总股本：13.09亿 |
| 报告期 | 2026-03-31 | 2025-12-31 | 2025-09-30 | 2025-06-30 |
| 公司类型 | 通用 | 通用 | 通用 | 通用 |
| 一、营业总收入 | 13,843,779,763.6 | 54,963,277,449.95 | 41,135,141,888.47 | 27,967,411,701.62 |
| 营业收入 | 13,843,779,763.6 | 54,963,277,449.95 | 41,135,141,888.47 | 27,967,411,701.62 |
| 二、营业总成本 | 13,504,978,803.17 | 53,921,722,737.41 | 40,346,990,541.21 | 27,397,599,436.31 |
| 营业成本 | 12,974,407,093.46 | 51,580,940,619.15 | 38,688,027,990.7 | 26,313,158,514.68 |
| 税金及附加 | 24,611,029.72 | 118,997,032.71 | 87,052,073.91 | 58,521,897.43 |
| 销售费用 | 286,479,151.72 | 1,199,699,696.55 | 853,806,411.04 | 553,796,458.6 |
| 管理费用 | 105,351,276.04 | 513,476,954.57 | 346,466,905.9 | 218,463,530.58 |
| 研发费用 | 7,611,588.1 | 46,789,558.57 | 25,902,194.31 | 18,480,170.5 |
| 财务费用 | 106,518,664.13 | 461,818,875.86 | 345,734,965.35 | 235,178,864.52 |
| 其中:利息费用 | 64,813,863.01 | 309,014,785.81 | 220,359,117.43 | 144,985,507.7 |
| 其中:利息收入 | 3,467,849.92 | 20,635,964.17 | 12,824,850.5 | 7,843,878.68 |
| 三、其他经营收益 | | | | |
| 加:公允价值变动收益 | 199,024.66 | 282,526.03 | 897,521.76 | 383,768.34 |
| 加:投资收益 | -1,433,268.66 | 4,793,861.74 | 1,144,013.41 | -1,476,139.27 |
| 资产处置收益 | 1,185,480.36 | 293,733,418.4 | 8,760,583.49 | 8,651,959.87 |
| 资产减值损失(新) | -2,385,726.25 | -25,113,091.63 | -5,365,609.36 | -3,827,050.29 |
| 信用减值损失(新) | -60,713,770.45 | -185,371,662.12 | -122,156,370.71 | -78,540,142.16 |
| 其他收益 | 9,028,992.95 | 30,226,515.95 | 19,978,906.85 | 13,177,443.67 |
| 四、营业利润 | 284,681,693.04 | 1,160,106,280.91 | 691,410,392.7 | 508,182,105.47 |
| 加:营业外收入 | 2,234,660.12 | 39,758,236.98 | 38,675,866.56 | 32,651,681.85 |
| 减:营业外支出 | 4,998,795.26 | 42,236,584.17 | 21,540,606.17 | 13,980,304.14 |
| 五、利润总额 | 281,917,557.9 | 1,157,627,933.72 | 708,545,653.09 | 526,853,483.18 |
| 减:所得税费用 | 70,220,113.31 | 324,959,057.2 | 178,789,080 | 147,103,953.74 |
| 六、净利润 | 211,697,444.59 | 832,668,876.52 | 529,756,573.09 | 379,749,529.44 |
| (一)按经营持续性分类 | | | | |
| 持续经营净利润 | 211,697,444.59 | 832,668,876.52 | 529,756,573.09 | 379,749,529.44 |
| (二)按所有权归属分类 | | | | |
| 归属于母公司股东的净利润 | 174,569,585.5 | 624,834,794.91 | 401,971,224.79 | 291,276,712.36 |
| 少数股东损益 | 37,127,859.09 | 207,834,081.61 | 127,785,348.3 | 88,472,817.08 |
| 扣除非经常损益后的净利润 | 168,888,007.4 | 421,334,367.89 | 371,153,677.17 | 261,657,491.87 |
| 七、每股收益 | | | | |
| (一)基本每股收益 | 0.14 | 0.48 | 0.31 | 0.22 |
| (二)稀释每股收益 | 0.12 | 0.43 | 0.28 | 0.2 |
| 八、其他综合收益 | -13,095,362.19 | -10,643,046.56 | -2,406,240.26 | -1,489,536.52 |
| 归属于母公司股东的其他综合收益 | -13,236,476.9 | -10,478,551.81 | -2,018,916.5 | -1,554,116.86 |
| 九、综合收益总额 | 198,602,082.4 | 822,025,829.96 | 527,350,332.83 | 378,259,992.92 |
| 归属于母公司股东的综合收益总额 | 161,333,108.6 | 614,356,243.1 | 399,952,308.29 | 289,722,595.5 |
| 归属于少数股东的综合收益总额 | 37,268,973.8 | 207,669,586.86 | 127,398,024.54 | 88,537,397.42 |
| 公告日期 | 2026-04-30 | 2026-04-11 | 2025-10-31 | 2025-08-30 |
| 审计意见(境内) | | 标准无保留意见 | | |